[Biz Journals] Sanofi (ADR) (NYSE:SNY)(TREND ANALYSIS) Selecta Biosciences has attracted another $38 million in funding to add to the $144 million it’s gotten over the past seven years according to Crunchbase, a big pile of cash even by biotech standards.
But one name that’s involved in today’s funding keeps cropping up in news coming out of the company: that of French drugmaker Sanofi, parent of the state’s biggest pharmaceutical developer, Genzyme Corp. And while Sanofi Genzyme Bioventures is not the largest investor in the Series E round being announced today, the participation from the venture arm of Sanofi comes with the express stipulation that the fund “only invests in early stage life science companies developing innovative products that may become future Sanofi products,” according to its website.
Stock Performance: Click here for a free comprehensive Trend Analysis Report
Sanofi (ADR) (NYSE:SNY) stock is currently trading 13.46% below its 52-week-high, 14.05% above its 52-week-low. The 1-year stock price history is in the range of $43.57 – $57.42. Sanofi (ADR) (SNY) has a price to earnings ratio of 24.35 versus Healthcare sector average of 53.82. SNY stock price has outperformed the S&P 500 by 16.5%. The Medical Drugs company is currently valued at $129.8 billion and its share price closed the last trading session at $49.69. The stock has a 50-day moving average of $51.75 and a 200-day moving average of $50.67.
Sanofi (ADR) (SNY) current short interest stands at 2.37 million shares. It has increased by 10% from the same period of last month. Around 1% of the company’s shares, which are float, are short sold. With a 10-days average volume of 1.25 million shares, the number of days required to cover the short positions stand at 1.9 days.
The company is expected to announce next quarter earnings on October 27, at consensus estimate of $0.87. Sanofi (ADR) (SNY) reported last quarter earnings on July 30. The Medical Drugs company announced earnings per share of $0.78 against a consensus Street estimate of $0.72, beating the average estimate by $0.06. This corresponds to a flat EPS compared to the same quarter of the previous fiscal year.
Is this a Buying Opportunity? Click here for a free Trend Analysis Report
There are currently twenty-nine analysts that cover Sanofi (ADR) stock. Of those twenty-nine, fifteen have a Buy rating, thirteen have a Hold rating and one has a Sell rating. On a consensus basis this yields to an Overweight rating. The consensus target price stands at $102.83.
A recent analyst activity consisted of Leerink Swann upgrading their Market Perform rating to Outperform on March 17. On the date of report, the stock closed at $47.39.
From an income perspective, Sanofi (ADR) (SNY) has a dividend yield of 3.32%. The dividend has remained flat over the last 5 years and the payout ratio stands at the high level of 79.09%.
Sanofi is a global pharmaceutical company that researches, develops and manufactures prescription pharmaceuticals and vaccines. The Company develops cardiovascular, thrombosis, metabolic disorder, central nervous system, internal medicine and oncology drugs, and vaccines.